About Lantheus Holdings, Inc. - Common Stock (LNTH)
Lantheus Holdings is a biotechnology company that specializes in developing and commercializing innovative diagnostic imaging agents and therapeutics primarily for oncology and other conditions. Their products include advanced molecular imaging agents that enhance the visualization of diseases in patients, enabling healthcare providers to make more informed decisions about diagnosis and treatment. The company is committed to advancing patient care through its focus on precision medicine, utilizing cutting-edge technologies to improve the detection and management of various diseases, particularly cancers, thus helping clinicians optimize patient outcomes. Read More
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 3.1% on continued negative momentum after a downgrade by Truist Securities, which cited concerns over competitive pressures and weaker-than-expected second-quarter results. The downgrade from "Buy" to "Hold" by Truist Securities included a significant price target reduction to $63 from $111.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 4.7% in the afternoon session after Truist Securities downgraded the stock from a "Buy" to a "Hold" rating and slashed its price target by over 43%. The downgrade, which cut the price target to $63 from $111, was driven by concerns over the performance of Lantheus's key radiopharmaceutical product, PYLARIFY. This follows the company's disappointing second-quarter results, where it missed both revenue and earnings estimates. Revenue fell 4.1% year-over-year to $378 million due to competitive pricing pressures. Compounding the issue, Lantheus also lowered its full-year financial guidance for revenue and earnings, signaling expectations for continued headwinds. The combination of missed Q2 targets, a reduced outlook, and the subsequent analyst downgrade has soured investor sentiment.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 4.1% year on year to $378 million. The company’s full-year revenue guidance of $1.49 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $1.57 per share was 6.3% below analysts’ consensus estimates.
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
fell 29.8% in the afternoon session after the company reported disappointing second-quarter financial results and slashed its full-year forecast. The radiopharmaceutical company announced quarterly revenue of $378 million and adjusted earnings per share of $1.57, both of which missed analysts' expectations. A key factor in the performance was an 8.3% decrease in sales for its main product, PYLARIFY, which faced increased competition. Compounding the issue, Lantheus lowered its full-year guidance significantly. The company projected full-year revenue between $1.47 billion and $1.51 billion, well below the consensus estimate of $1.57 billion. Similarly, its earnings per share forecast of $5.50 to $5.70 fell far short of the anticipated $6.64.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 4.1% year on year to $378 million. The company’s full-year revenue guidance of $1.49 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $1.57 per share was 6.3% below analysts’ consensus estimates.
Lantheus Holdings (LNTH) Q2 2025 earnings miss estimates, revenue down 4.1%. Shares drop 20.8% as weak guidance raises concerns. FDA accepts NDA for PYLARIFY upgrade.
BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its second quarter ended June 30, 2025.
Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resiliencePDUFA date set for March 6, 2026
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH)
will be reporting earnings this Wednesday before market hours. Here’s what investors should know.
Lantheus Holdings (LNTH) is a standout value stock with strong financials, low P/E ratios, and high profitability, making it an attractive pick for value investors.
BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025.
BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025.
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
